RNXT stock
RenovoRx Hits 52-Week High as Revenue and Trial News Align
RenovoRx spent August checking boxes most microcap biotechs take years to check. A pivotal trial finished enrolling. Quarterly revenue kept climbing. A Nasdaq compliance problem got resolved. By month’s end, the stock was sitting at a 52-week high. RenovoRx Hits 52-Week High as Revenue Growth and Trial Enrollment Both Deliver RenovoRx (Nasdaq: RNXT) shares rose…
